Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kalaco Scientific
Scottsdale, Arizona, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Kalaco Scientific developed the Nexalin electrostimulation medical device intended for transcranial electronic stimulation to treat symptoms of depression and possibly other neuropsychiatric conditions. A Phase II clinical trial was conducted to assess safety and efficacy in mild-to-moderate depression; results are not publicly detailed beyond completion status. The company has also been associated with citalopram hydrobromide in its pipeline database entries, but this is likely due to involvement in related trials rather than drug development itself.
- Therapeutic areas
- Psychiatry
- Modalities
- DeviceElectrotherapy device
- Industry
- Therapeutic Medical Devices
Beyond the preview
Go deeper on Kalaco Scientific.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kalaco Scientific.